Final approval for Sympazan, the oral soluble film formulation of clobazam, is pending the expiration of the orphan drug exclusivity period for ONFI.
The sugar-removing enzyme may lessen the demand for universal blood donors.
Survivors of breast cancer and their families face long-term cumulative financial implications from treatment and associated costs.
Even as market disruptors such as Amazon raise concerns, pharmacies prove that the services they provide yield valuable patient experiences.
Combining pembrolizumab (Keytruda) and an investigational drug could benefit patients with advanced melanoma who have not responded to immunotherapy treatment.
Top news of the day from across the health care landscape.

Most Popular

Company Profile >
Contributors >
Industry Guide >
Market News >
Peer Exchange >
Conferences >
Subscribe >
Specialty Times Resources
About Us
Contact Us
Terms & Conditions
MJH Associates >
Pharmacy Times
American Journal of Managed Care
MD Magazine
Targeted Oncology
Physicians' Education Resource
Pharmacy & Healthcare Communications, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright Specialty Pharmacy Times 2006-2018
Pharmacy & Healthcare Communications, LLC. All Rights Reserved.